In TNBC, LSD1 epigenetically silences chemokines that attract cytotoxic T-cells, as well as PD-L1, while inhibition of LSD1 improves T-lymphocyte trafficking to the tumor microenvironment and the response to immune checkpoint blockade (Qin et al., 2019). The gene discussed is KDM1A; the disease is neoplasm.